Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19 von Berry, Donald A, Ip, Andrew, Lewis, Brett E, Berry, Scott M, Berry, Nicholas S, MrKulic, Mary, Gadalla, Virginia, Sat, Burcu, Wright, Kristen, Serna, Michelle, Unawane, Rashmi, Trpeski, Katerina, Koropsak, Michael, Kaur, Puneet, Sica, Zachary, McConnell, Andrew, Bednarz, Urszula, Marafelias, Michael, Goy, Andre H, Pecora, Andrew L, Sawczuk, Ihor S, Goldberg, Stuart L

Volltext

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocy... von Mato, Anthony R., Foon, Kenneth A., Feldman, Tatyana, Schuster, Stephen J., Svoboda, Jakub, Chow, Kar Fai, Valentinetti, Marisa, Mrkulic, Mary, Azzollini, Kelly, Gadaleta, Gabriella, Bhattacharyya, Pritish K., Zenreich, Joshua, Pascual, Lauren‐Nicole, Yannotti, Kara, Kdiry, Sabrina, Howlett, Christina, Strelec, Lauren, Porter, David, Bejot, Coleen, Goy, André

Volltext

A Phase I/II Study of Reduced Dose FCR (FCR-lite) in Combination with Lenalidomide Followed By Lenalidomide Maintenance (FCR2) for Initial Therapy of CLL: Final Results and Long-Te... von Mato, Anthony R., Goy, Andre, Feldman, Tatyana A, Rhodes, Joanna, Leslie, Lori A., Mrkulic, Mary, Kdiry, Sabrina, Yannotti, Kara, Valentinetti, Marisa, Schuster, Stephen J., Svoboda, Jakub, Foon, Kenneth, Skarbnik, Alan P

Volltext